Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported fourth quarter and full year 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results